Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its Psychedelic Drug Candidates Pipeline With Novel DMT & 5-MeO-DMT Analogs
Toronto, Ontario--(Newsfile Corp. - March 15, 2021) - Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) ("Mindset" or the "Company") is pleased to announce that it has filed a sixth provisional patent application with the United States Patent and Trademark Office. This most recent patent application covers a comprehensive range of novel N,N-Dimethyltryptamine ("DMT") and 5-methoxy-N,N-dimethyltryptamine ("5-MeO-DMT") analogs, their related chemical process synthesis, composition of matter and...
2021-03-15 7:00 AM EDT
Mindset Pharma to Present at the Stifel GMP Conference - Psychedelics: Addressing the Global Mental Health Crisis
Toronto, Ontario--(Newsfile Corp. - March 10, 2021) - Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) ("Mindset" or the "Company"), a biotechnology company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce that James Lanthier, CEO, and Joseph Araujo, CSO, will be presenting at the Stifel GMP Conference - Psychedelics: Addressing the Global Mental Health Crisis. Date: Thursday, March 11, 2021, 1:50 pm ESTTo register for the...
2021-03-10 9:13 AM EST
Mindset Pharma Appoints Leading Molecular Pharmacologist & Formulation Expert Dr. Joseph Gabriele to Scientific Advisory Board
Toronto, Ontario--(Newsfile Corp. - March 8, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company") is pleased to announce that it has appointed Dr. Joseph Gabriele, a molecular pharmacologist specializing in signal transduction within the central nervous system, to its scientific advisory board ("Scientific Advisory Board"). Dr. Gabriele specializes in molecular pharmacology, transdermal delivery and formulation chemistry with pharmaceutical, natural molecules. In...
2021-03-08 7:00 AM EST
Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process
Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has engaged a leading international contract development and manufacturing organization ("CDMO") to synthesize a 1.0 kg batch of cGMP (i.e. pharmaceutical grade) psilocybin utilizing Mindset's...
2021-02-22 7:00 AM EST
Mindset Pharma Added to North American Psychedelics Index
Toronto, Ontario--(Newsfile Corp. - February 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that effective today, it has been added to the North American Psychedelics Index which is provided by German-based index provider, Solactive (the "Index"). The Index is designed to provide a measure of the...
2021-02-19 7:00 AM EST
Mindset Pharma Announces U.S. Listing Application for OTCQB Venture Market
Toronto, Ontario--(Newsfile Corp. - February 17, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTC PINK: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has applied to the OTC Markets Group to begin trading on the OTCQB Venture Market ("OTCQB"). Currently, the Company trades on the OTC Pink Sheets under the symbol "MSSTF". The...
2021-02-17 7:00 AM EST
Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates
Toronto, Ontario--(Newsfile Corp. - February 10, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that several of its proprietary, novel and diverse psychedelic compounds are demonstrating strong potency and efficacy, superior to psilocybin in in vivo proof-of-concept ("PoC") studies. These PoC results in...
2021-02-10 7:00 AM EST
Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds
Toronto, Ontario--(Newsfile Corp. - February 5, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a leading drug discovery and development company focused on the development novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce that the Company has filed 3 final patent applications with the U.S. Patent and Trademark Office ("USPTO").The patent applications cover a comprehensive range of novel diverse proprietary...
2021-02-05 7:00 AM EST
Mindset Pharma Retains Corporate Development Advisors
Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has engaged the services of Black Vulcan Resources, LLC ("Black Vulcan") and Angstrom Capital Ltd. ("Angstrom" and together with Black Vulcan, the "Consultants") to assist the Company with business strategy...
2021-02-01 6:56 PM EST
Mindset Selects Compounds from Its Third Psilocybin-Inspired Drug Family to Move into in vivo PoC Studies
Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has selected a subset of representative compounds belonging to its proprietary third family of patent-pending next generation psychedelic compounds to move into in vivo Proof-of-Concept ("PoC")...
2021-02-01 7:00 AM EST
Mindset Pharma Announces Listing on the Frankfurt Stock Exchange
Toronto, Ontario--(Newsfile Corp. - January 27, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that its common shares have been accepted for listing on the Frankfurt Stock Exchange (the "FSE") and commenced trading today under the symbol "9DF". As a result, the Company's common shares are now...
2021-01-27 8:45 AM EST
Mindset Pharma to Present at Inaugural KCSA Psychedelic Investor Conference
Toronto, Ontario--(Newsfile Corp. - January 20, 2021) - Mindset Pharma Inc. (CSE:MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has been invited to present at the inaugural KCSA Psychedelic Investor Conference being held on Tuesday, January 26, 2021 at 9:45 am E.T.James Lanthier, CEO of Mindset, commented, "Mindset is thrilled to present at...
2021-01-20 7:00 AM EST
Mindset Pharma Invited to Present at Upcoming Canaccord Genuity Mental Health Conference
Toronto, Ontario--(Newsfile Corp. - January 14, 2021) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce it has been invited to present at the Canaccord Genuity conference "New Paradigms & Treatment Approaches in Mental Health", being held February 3-4, 2021.James Lanthier, CEO of Mindset, commented, "Mindset is pleased to present...
2021-01-14 7:00 AM EST
Mindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of Potential Clinical Use Cases Including Micro-Dosing
Toronto, Ontario--(Newsfile Corp. - January 6, 2021) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that certain compounds belonging to its third family of patent-pending next generation psychedelic compounds are exhibiting positive in vitro...
2021-01-06 7:00 AM EST
Mindset Engages Hybrid Financial Inc.
Toronto, Ontario--(Newsfile Corp. - December 31, 2020) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that the Company has entered into an arm's-length marketing agreement (the "Marketing Agreement") with Hybrid Financial Inc. ("Hybrid"). As...
2020-12-31 4:45 PM EST
Mindset Further Expands Portfolio of Psychedelic Drug Candidates with Third U.S. Provisional Patent Application; 50 Total New Psychedelic Patent-Pending Compounds Synthesized
Toronto, Ontario--(Newsfile Corp. - December 29, 2020) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has filed another provisional patent application with the United States Patent and Trademark Office. Mindset has synthesized several...
2020-12-29 7:30 AM EST
Mindset Pharma to Commence Trading on the CSE on December 23, 2020 Under the Symbol "MSET"
Toronto, Ontario--(Newsfile Corp. - December 22, 2020) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange ("CSE") effective at the open of business on Wednesday, December 23,...
2020-12-22 12:19 PM EST
Mindset Pharma Announces Closing of Non-Brokered Private Placement, Increasing Aggregate Gross Proceeds Raised to $5,000,000
Toronto, Ontario--(Newsfile Corp. - December 16, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has closed an additional non-brokered private placement, pursuant to which the Company issued an aggregate of 2,021,187 units (a "Unit") of the Company at a price of $0.40...
2020-12-16 7:03 PM EST
Mindset Pharma Announces Upsizing and Closing of $4.17 Million Brokered Private Placement Financing
Toronto, Ontario--(Newsfile Corp. - December 15, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has upsized and completed its previously announced brokered private placement, led by Mackie Research Capital Corporation, as sole agent and sole bookrunner (the "Agent"),...
2020-12-15 2:06 PM EST
Mindset Pharma Closes Ontario Brain Institute Funding and Announces Private Placement Offering
Toronto, Ontario--(Newsfile Corp. - November 9, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has entered into a secured convertible promissory note transaction with the Ontario Brain Institute ("OBI"). OBI is a provincially funded, not-for-profit organization that...
2020-11-09 3:30 PM EST